Effect of probiotic, curcumin, and curcumin-probiotic on quality of life, anxiety, stress, and depression

Investigating the Effect of Functional Edible Powders Enriched with Probiotics, Curcumin, or Their Combination on Quality of Life, Depression, anxiety, and Stress in Overweight or Obese Individuals with Metabolic Syndrome: a Randomized, double-blind, controlled clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220315054289N2

Enrollment

128

Registered

2023-02-18

Start date

2023-03-06

Completion date

Unknown

Last updated

2023-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Syndrome. Metabolic syndrome

Interventions

Intervention 1: Intervention group 1: Dissolve and receive curcumin-enriched edible functional powder containing 1000 mg of curcumin (Karen Pharma and Food Supplement Co.) in water daily for 8 weeks.

Eligibility

Sex/Gender

All

Age

30 Years to 65 Years

Inclusion criteria

Inclusion criteria: Aged 30 - 65 years Overweight (BMI between 25 to 29.9) or obese (BMI over 30) individuals with metabolic syndrome based on ATP III criteria Not suffering from metabolic, endocrine, or cardiovascular disease (except diabetes, dyslipidemia, and hypertension) at baseline Not suffering from kidney, liver, or systemic diseases at the beginning of the study Not infected with Covid-19 or any other infections for 3 months before the study No history of hospitalization for 3 months prior to the study Has not used antibiotics for 3 months before beginning the study Has not taken curcumin and probiotic supplements, or supplements for 3 months before the study

Exclusion criteria

Exclusion criteria: Pregnancy Lactating

Design outcomes

Primary

Measure	Time frame
Quality of Life. Timepoint: At the beginning of the study (before the intervention) and the end of the study (8 weeks after the intervention). Method of measurement: SF-36 questionnaire.;Depression, Anxiety and Stress. Timepoint: At the beginning of the study (before the intervention) and the end of the study (8 weeks after the intervention). Method of measurement: DASS-21 questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Ali Mohsenpour

Shiraz University of Medical Sciences

mohammadali.mohsenpour@gmail.com+98 71 3725 8099

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026